Ambroise-Thomas P, Schweitzer M, Pinon J M, Thiebaugeorges O
Service de Parasitologie-Mycologie, CHU-38043 Grenoble.
Bull Acad Natl Med. 2001;185(4):665-83; discussion 684-8.
In France, a national program for the prevention of congenital toxoplasmosis has been set up 25 years ago. This program is here presented and discussed in details. It is based on a decision tree well defined, with pre and/or per gravidic serological screening with several different tests, completed, if necessary, by ultrasounds examinations of the fetus, biomolecular tests (PCR) on amniotic fluid, and by clinical, biological, and radiological surveillance of neo-nates. The purpose of this prevention program is to: 1/identify nonimmune young women and limit their contamination risk during pregnancy by appropriate counseling on hygiene and diet; 2/screen and treat per gravidic toxoplasmosis as early as possible so as to prevent or limit transmission to the fetus and its consequences. 3/in utero diagnose and treat infestation of the fetus; 4/diagnose and treat asymptomatic congenital toxoplasmosis in neonates, to prevent risks of reactivation and late complications, especially ocular. Such a prevention program has a cost validated by the prevalence of acquired toxoplasmosis in adults in France (over 50% of the population) and by the yearly incidence of congenital toxoplasmosis (at least 0.1% of births according to the best hypothesis). These 6 to 700 congenital toxoplasmosis cases per year may be compared to the 6 to 7,000 per gravidic seroconversions which could lead to fetal contamination if no preventive measures are taken. Nevertheless, as it is often the case in the field of prevention, it is very difficult to statistically assess the efficacy of this program even though several arguments show that it allows to eliminate the most serious toxoplasmosis, sources of serious handicaps at birth, and to limit the frequency of late complications (especially retino-choroiditis) of asymptomatic infections in neonates. The position of European countries varies as to prevention of congenital toxoplasmosis. Some countries (Austria, Belgium) have national prevention programs similar to the French one, whereas others have set up only limited programs or set up no systematic prevention. These differences may be accounted for by the different frequencies of toxoplasmic risk. It seems mandatory to forget all dogmatism and not to stick to a strictly statistical approach for a disease with not only medical but also social and human consequences.
25年前,法国设立了一项预防先天性弓形虫病的国家计划。本文将详细介绍并讨论该计划。它基于一个定义明确的决策树,通过多种不同检测手段进行孕前和/或孕期血清学筛查,必要时辅以胎儿超声检查、羊水生物分子检测(PCR),以及对新生儿的临床、生物学和放射学监测。该预防计划的目的是:1/识别非免疫的年轻女性,并通过适当的卫生和饮食咨询,在孕期限制她们的感染风险;2/尽早筛查和治疗孕期弓形虫病,以预防或限制其传播给胎儿及其后果;3/在子宫内诊断和治疗胎儿感染;4/诊断和治疗新生儿无症状先天性弓形虫病,以预防复发风险和晚期并发症,尤其是眼部并发症。这样一项预防计划的成本已根据法国成年人后天性弓形虫病的患病率(超过50%的人口)以及先天性弓形虫病的年发病率(根据最佳假设,至少占出生人口的0.1%)得到验证。每年这600至700例先天性弓形虫病病例可与6000至7000例孕期血清转化病例相比较,如果不采取预防措施,这些血清转化病例可能导致胎儿感染。然而,正如预防领域常见的情况那样,即使有若干论据表明该计划能够消除最严重的弓形虫病(出生时严重残疾的根源),并限制新生儿无症状感染的晚期并发症(尤其是视网膜脉络膜炎)的发生率,但很难从统计学上评估该计划的效果。欧洲国家在先天性弓形虫病预防方面的立场各不相同。一些国家(奥地利、比利时)有与法国类似的国家预防计划,而其他国家仅设立了有限的计划或未建立系统的预防措施。这些差异可能是由弓形虫感染风险的不同频率所致。对于这样一种不仅具有医学后果,还具有社会和人文后果的疾病,摒弃所有教条主义,不局限于严格的统计方法似乎是必要的。